S-KRAL Clinical Monograph & Batch COA
Certified DCGI Formulation Literature (PDF)
S-KRAL
Oxetacaine 20mg + Sucralfate 1gm
S-KRAL is an advanced gastro-protective formulation developed for the rapid healing of mucosal erosion, acid peptic disorders, and gastroesophageal reflux disease (GERD).
Clinical Pharmacology & Therapeutic Profile
Comprehensive therapeutic guidelines for medical practitioners and institutional procurement
Therapeutic Indications
Mechanism of Action (MOA)
Forms a polyanionic protective barrier coating over inflamed gastric ulcers, preventing enzymatic acid degradation while facilitating tissue re-epithelialization.
Administer on an empty stomach 1 hour before principal meals, or as posology prescribed by the gastroenterologist.
Well tolerated under clinical supervision. Contraindicated in patients with hypersensitivity to active ingredients.
Store below 25°C. Do not freeze. Keep container tightly closed.
WHO-GMP Certified Purity
Manufactured in state-of-the-art HVAC controlled cleanrooms with 100% active ingredient bio-potency and analytical batch testing.
Alu-Alu Moisture Barrier
Superior barrier protection against tropical humidity, preventing physical degradation and guaranteeing 24-month stability.
Exclusive District Monopoly
Strict PCD franchise monopoly allocation ensuring zero price competition and complete territory protection for our partners.
Technical Product Specifications
Active Medical Composition
S-KRAL features Oxetacaine 20mg + Sucralfate 1gm prepared to high pharmaceutical purity standards.
*Disclaimer: Formulations are intended solely for distribution to licensed practitioners, hospitals, and pharmacies. Dosage must adhere to medical advice.
Customer & Clinical Reviews
Real feedback from registered physicians, stockists, PCD franchise partners, and verified buyers.
Based on 1 verified review
Maintained as a staple formulation for S-KRAL
S-KRAL has been maintained as a staple formulation in our prescribing protocols, demonstrating excellent therapeutic adherence throughout the full prescribed regimen. Cartons arrive in reinforced corrugated shippers with intact tamper seals and verified analytical documentation. We maintain uninterrupted inventory because doctors frequently request this specific brand.
Questions Regarding S-KRAL
What is the therapeutic indication and composition of S-KRAL?
S-KRAL contains Oxetacaine 20mg + Sucralfate 1gm indicated for Peptic Ulcer Disease as formulated by Sygnus Biotech.
What packaging presentations are available for S-KRAL?
S-KRAL is supplied in tamper-evident 100ml / 200ml PET Bottle with Graduated Measuring Cap, engineered with barrier foil protection to ensure a 24 to 36 month shelf life.
Is monopoly PCD franchise territory available for S-KRAL?
Yes, Sygnus Biotech grants exclusive district-wise monopoly marketing rights for S-KRAL along with promotional visual aids, product cards, and marketing support.
What is the regulatory schedule and minimum order quantity (MOQ)?
S-KRAL is categorized as Schedule H with an introductory PCD franchise MOQ of 100 units per batch.
Related Formulations in Syrup
View all Syrup →
SB CAIN GEL 200ML
Oxetacaine 10mg + Aluminium Hydroxide 0.291gm
TRYLAX
Liquid Paraffin 1.25ml + Milk of Magnesia 3.75ml + Sodium Picosulphate 3.33mg
SYPROVIT
Cyproheptadine HCl 2mg + Tricholine Citrate 0.275mg
SBFLAME 60ML
Ibuprofen 100mg + Paracetamol 162.5mg